Edison issues update on Immunovia (IMMNOV)
LONDON, UK / ACCESSWIRE / December 21, 2016 / Immunovia (IMMNOV.ST) has taken key steps in both opportunities being pursued for its IMMray PanCan-d test for the early detection of pancreatic cancer. In diabetes, a collaboration with the Early Detection Research Network (EDRN), part of the US National Cancer Institute (NCI), is an important step forwards as it could lead to the start of the required clinical study. Diabetes is the larger of the two indications with 3.4 million newly diagnosed diabetes patients every year in the US and EU. In high-risk pancreatic cancer patients, Immunovia has now started a prospective clinical trial, as expected. This is a smaller opportunity (c 200k patients) but could generate initial revenues in 2018. Our valuation remains SEK155.2/share.
We have made no changes to our financial forecasts and maintain our rNPV valuation of SEK155.2 per share (SEK149.6 diluted), assuming a penetration rate of 35% in patients at high risk of pancreatic cancer and 5% in newly diagnosed diabetic patients, which targets total peak sales of c SEK2.1bn for both groups. The start of the formal clinical trial in diabetes could lead to an increase in our current 60% probability of success in this opportunity.
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website www.edisoninvestmentresearch.com.
About Edison: Edison is an international equity research firm with a team of over 70 analysts, investment and roadshow professionals and works with both large and smaller capitalised companies, blue chip institutional investors, wealth managers, private equity and corporate finance houses to support their capital markets activity. Edison provides services to more than 420 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.
For more information
please contact:
Juan Pedro Serrate Edison Investment Research +44 (0)20 3681 2534
Lala Gregorek Edison Investment Research +44 (0)20 3681 2527 healthcare@edisongroup.com
Contact details: Learn more at www.edisongroup.com and connect with Edison on:
www.linkedin.com/company/edison-investment-research
www.twitter.com/Edison_Inv_Res
YouTube
Google+
https://plus.google.com/105425025202328783163/posts
SOURCE: Edison Investment Research
ReleaseID: 451518
Copyright © 1999-2013 SproutNews.com
